Clinical Focus

  • Ped Hematology/Oncology
  • Pediatric Hematology-Oncology

Academic Appointments

Professional Education

  • Fellowship: Stanford University Pediatric Hematology Oncology Fellowship (2009) CA
  • Residency: United States Naval Medical Center San Diego Pediatric Residency (2003) CA
  • Medical Education: New York Medical College Registrar (1998) NY
  • Board Certification: American Board of Pediatrics, Pediatric Hematology-Oncology (2011)
  • Board Certification: American Board of Pediatrics, Pediatrics (2003)

2021-22 Courses

All Publications

  • A challenging case of recurrent idiopathic hemophagocytic lymphohistiocytosis (HLH) initially presenting in an infant with Pneumocystis jirovecii pneumonia Solomon, B., Balagtas, J., Chien, M., Pooni, R., Balboni, I., Weinacht, K., Gernez, Y. SPRINGER/PLENUM PUBLISHERS. 2021: S55
  • P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs). Subramaniam, S., Toner, G. C., Stockler, M. R., Martin, A., Pashankar, F. D., Tran, B., Jeffery, M., Mazhar, D., Huddart, R. A., Walpole, E., Stevanovic, A., Wyld, D., Hanning, F. J., Wheater, M., Balagtas, J. R., Troon, S., Birtle, A., White, J. D., Grimison, P. S., Australian New Zealand Urogenital LIPPINCOTT WILLIAMS & WILKINS. 2021
  • The identification of at-risk patients and prevention of venous thromboembolism in pediatric cancer: guidance from the SSC of the ISTH JOURNAL OF THROMBOSIS AND HAEMOSTASIS Tullius, B. P., Athale, U., Van Ommen, C. H., Chan, A. C., Palumbo, J. S., Balagtas, J. S., Subcomm Hemostasis & Malignan, Subcomm Pediat Neonatal Throm 2018; 16 (1): 175–80

    View details for DOI 10.1111/jth.13895

    View details for Web of Science ID 000419402000023

    View details for PubMedID 29178421

  • Rate of abnormal vaginal bleeding and contraception counseling in women undergoing chemotherapy JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY Cutler, K. E., Creinin, M. D., Balagtas, J. S., Hou, M. Y. 2016; 14 (8): 337–41

    View details for DOI 10.12788/jcso.0290

    View details for Web of Science ID 000398367400004

  • Subcutaneous Panniculitis-Like T-Cell Lymphoma: Pediatric Case Series Demonstrating Heterogeneous Presentation and Option for Watchful Waiting PEDIATRIC BLOOD & CANCER Johnston, E. E., LeBlanc, R. E., Kim, J., Chung, J., Balagtas, J., Kim, Y. H., Link, M. P. 2015; 62 (11): 2025-2028


    Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) and primary cutaneous gamma delta T-cell lymphoma (PCGD-TCL) were initially both classified as subcutaneous panniculitis-like T-cell lymphoma. In 2008, SPTCL with alpha-beta T-cell receptor subtype was separated from primary cutaneous gamma delta T-cell lymphomas (PCGD-TCL). We report four pediatric cases that demonstrate the heterogeneity of each disease and show that PCGD-TCL in children can have an indolent course, whereas SPTCL can behave aggressively. Three patients had spontaneous, durable remissions without treatment, whereas the one patient with disease progression was treated successfully. Watchful waiting may thus be appropriate for initial management of children.

    View details for DOI 10.1002/pbc.25626

    View details for PubMedID 26146844

  • Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types. PLoS genetics Giacomini, C. P., Sun, S., Varma, S., Shain, A. H., Giacomini, M. M., Balagtas, J., Sweeney, R. T., Lai, E., Del Vecchio, C. A., Forster, A. D., Clarke, N., Montgomery, K. D., Zhu, S., Wong, A. J., van de Rijn, M., West, R. B., Pollack, J. R. 2013; 9 (4)

    View details for DOI 10.1371/journal.pgen.1003464

    View details for PubMedID 23637631

  • Therapeutic Complications in a Patient With High-Risk Acute Lymphoblastic Leukemia and Undiagnosed Hereditary Hemochromatosis PEDIATRIC BLOOD & CANCER Balagtas, J. M., Dahl, G. V. 2012; 58 (1): 101-103


    Hereditary hemochromatosis (HH) is an autosomal-recessive disorder of iron metabolism that most commonly manifests in the fourth or fifth decade of life. Here, we describe a 14-year-old male who presented with high-risk acute lymphoblastic leukemia and previously undiagnosed HH. His treatment course was remarkable for significant therapeutic complications, including iron overload, hepatic failure, cardiac dysfunction, and death. Postmortem testing revealed homozygosity for the C282Y mutation, confirming the diagnosis of HH. Since HH mutations occur commonly in select populations, screening patients with leukemia for HH may better inform treatment decisions regarding chemotherapy, transfusions, and/or iron chelation therapy.

    View details for DOI 10.1002/pbc.22829

    View details for Web of Science ID 000297641300020

    View details for PubMedID 22076832

  • Liposomal amphotericin B associated with severe hyperphosphatemia PEDIATRIC INFECTIOUS DISEASE JOURNAL Sutherland, S. M., Hong, D. K., Balagtas, J., Gutierrez, K., Dvorak, C. C., Sarwal, M. 2008; 27 (1): 77-79


    We report 4 patients who developed hyperphosphatemia while receiving liposomal amphotericin B to treat an invasive fungal infection. Resolution of the hyperphosphatemia occurred after transition to amphotericin B lipid complex. This phenomenon may occur more commonly in patients with mild to moderate renal insufficiency.

    View details for DOI 10.1097/INF.0b013e31815922a3

    View details for PubMedID 18162947